HeartSciences Inc. (HSCS) - Form 8-K Summary
Business Context and Reporting Period
HeartSciences Inc., a Texas corporation, filed this Current Report on Form 8-K on August 3, 2025. The filing reports the entry into a material definitive agreement regarding the company's equity distribution program.
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The document focuses on capital raising capacity and market value constraints:
- Aggregate Market Value: As of July 31, 2025, the aggregate market value of outstanding common stock held by non-affiliates was $14,737,609.
- Share Count: 2,276,253 shares held by non-affiliates as of July 31, 2025.
- Reference Price: $5.73 per share (closing price on July 10, 2025).
- Recent Sales: The company has not sold any shares pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to this report.
Material Changes
On August 3, 2025, the Company entered into Amendment No. 3 to its Equity Distribution Agreement (EDA) with Maxim Group LLC. Key changes include:
- Increased Offering Capacity: The maximum amount of common stock available for sale under the "at the market" offering was increased from $15,000,000 to $25,000,000.
- Revised Commission Structure: Maxim Group's compensation rate is now 4.0% on gross proceeds up to $11,036,310 and 3.0% on gross proceeds exceeding that amount.
Guidance, Risks, and Contingencies
The filing outlines specific regulatory constraints and risks associated with the offering:
- Form S-3 Eligibility: Sales are subject to the eligibility requirements of Form S-3. Specifically, the company cannot sell shelf securities in a public primary offering exceeding one-third of the aggregate market value of shares held by non-affiliates in any 12-month period while that value remains below $75 million.
- Emerging Growth Company Status: The registrant is an emerging growth company.
- Legal Validity: The validity of the additional shares is supported by a legal opinion from Foley Shechter Ablovatskiy LLP.
Investor Verification Checklist
- Verify the current aggregate market value of non-affiliate shares to confirm the remaining capacity under the one-third Form S-3 limitation.
- Review the full text of Amendment No. 3 (Exhibit 1.4) for specific termination rights or additional covenants not summarized here.
- Monitor future 8-K filings for actual sales executed under the amended EDA and the resulting dilution impact.
- Confirm the company's continued status as an emerging growth company and any implications for financial reporting standards.